Taken together with the previously reported association between elevated WSB1 expression and high tumor grade, these survival data demonstrated that WSB1 overexpression was correlated with unfavorable prognosis, suggesting WSB1 as a clinical biomarker for prostate cancer. This evidence concerns the gene WSB1 and neoplasm.